QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
QIAGEN N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$46.55+0.42 (+0.91%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 24.0
- Dividend yield
- 0.54%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
62.2%−3.7 pts over 5 years
Operating margin
22.3%+1.6 pts over 5 years
Net margin
20.3%+1.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.7% | -0.8% | +2.2% | +5.0% | |
| Gross profit | +34.3% | -2.1% | +1.1% | +4.6% | |
| Operating income | +376.8% | -4.3% | +3.8% | +10.0% | |
| Net income | +408.3% | +0.1% | +3.4% | +12.6% | |
| EPS, diluted | +424.3% | +1.8% | +4.9% | +13.4% | |
| Free cash flow | -10.5% | -8.2% | +6.9% | +7.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 3.1% | 13.5% | 11.6% | |
| Return on assets | 1.9% | 6.5% | 7.1% | |
| Current ratio | 3.36 | 2.84 | 3.90 | |
| Debt to equity | 0.41 | 0.69 | 0.44 | |
| Net debt to EBITDA | 2.01× | 2.24× | 1.24× | |
| Interest coverage | 2.5× | 5.4× | 14.0× | |
| Inventory turnover | 3.6× | 2.8× | 2.7× | |
| Capex to revenue | 5.6% | 7.1% | 9.6% | |
| Diluted shares | 239M | 234M | 219M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Qiagen generated $3.14B from operations and spent $1.56B on capital expenditure, dividends and share buybacks. 54% of that went back into the business.
Generated
$3.14B
Used
$1.56B
Capital expenditure$837.06M54%Dividends$54.24M3%Share buybacks$672.17M43%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin20.3%
×Asset turnover0.35×
×Equity multiplier1.63×
=Return on equity, FY202511.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 20.3% | 0.35× | 1.63× | 11.6% |
| FY2024 | 4.2% | 0.34× | 1.60× | 2.3% |
| FY2023 | 17.4% | 0.32× | 1.71× | 9.4% |
| FY2022 | 19.8% | 0.34× | 1.89× | 12.9% |
| FY2021 | 22.8% | 0.37× | 2.04× | 17.4% |
| FY2020 | 19.2% | 0.34× | 2.08× | 13.5% |
| FY2019 | -2.7% | 0.28× | 2.12× | -1.6% |
| FY2018 | 12.7% | 0.28× | 2.08× | 7.4% |
| FY2017 | 2.8% | 0.30× | 1.82× | 1.6% |
| FY2016 | 6.0% | 0.32× | 1.64× | 3.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$424.88M
- Cash generatingOperating cash flow above zero$654.33M
- Return on assets improvedROA up on the prior year1.4% → 7.5%
- Earnings backed by cashOperating cash flow above net income$654.33M vs $424.88M
- Less leverageLong-term debt to assets fell14.8% → 26.3%
- Better liquidityCurrent ratio rose1.88 → 3.90
- No dilutionShare count did not rise225M → 219M
- Gross margin improvedGross margin up on the prior year48.90% → 62.18%
- More efficientAsset turnover rose0.32 → 0.37